Literature DB >> 28543368

Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.

Keiko Sakamoto1, Taisuke Ito2, Fumihiko Tanioka3, Hidekazu Fukamizu4, Yoshiki Tokura2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28543368     DOI： 10.1111/1346-8138.13915

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

1.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

2.  Genetic Panel Test of Double Cancer of Signet-Ring Cell/Histiocytoid Carcinoma of the Eyelid and Papillary Thyroid Carcinoma: Case Report and Literature Review.

Authors:  Masashi Kuroki; Hirofumi Shibata; Bunya Kuze; Toshimitsu Ohashi; Keishi Kohyama; Hisakazu Kato; Hiroki Kato; Tatsuhiko Miyazaki; Hiroyuki Tomita; Takenori Ogawa
Journal:  Cureus       Date:  2022-05-21

3.  Diagnostic and treatment challenges of a case of primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid.

Authors:  Mathew M Palakkamanil; Muhammad N Mahmood; Audrey Chan
Journal:  BMC Ophthalmol       Date:  2020-10-14       Impact factor: 2.209

4.  Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents.

Authors:  Lei-Chi Wang; Tai-Chi Lin; Yi-Chen Yeh; Hsiang-Ling Ho; Chieh-Chih Tsai; Teh-Ying Chou
Journal:  Curr Oncol       Date:  2021-02-16       Impact factor: 3.677
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.